Log in

NYSE:PKI - PerkinElmer Stock Price, Forecast & News

$74.80
-4.21 (-5.33 %)
(As of 03/29/2020 01:19 AM ET)
Today's Range
$73.34
Now: $74.80
$77.39
50-Day Range
$66.71
MA: $83.99
$96.50
52-Week Range
$62.91
Now: $74.80
$103.00
Volume733,664 shs
Average Volume1.15 million shs
Market Capitalization$8.33 billion
P/E Ratio36.67
Dividend Yield0.35%
Beta1.33
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Read More
PerkinElmer logo

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
CUSIP71404610
Phone781-663-6900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.88 billion
Cash Flow$5.94 per share
Book Value$25.33 per share

Profitability

Net Income$227.56 million

Miscellaneous

Employees13,000
Market Cap$8.33 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.


PerkinElmer (NYSE:PKI) Frequently Asked Questions

How has PerkinElmer's stock been impacted by COVID-19 (Coronavirus)?

PerkinElmer's stock was trading at $72.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PKI shares have increased by 2.7% and is now trading at $74.80. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PerkinElmer?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 9 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for PerkinElmer.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for PerkinElmer.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) posted its quarterly earnings data on Monday, January, 27th. The medical research company reported $1.35 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.32 by $0.03. The medical research company earned $805.50 million during the quarter, compared to analysts' expectations of $801.14 million. PerkinElmer had a return on equity of 16.80% and a net margin of 7.89%. PerkinElmer's revenue was up 6.5% on a year-over-year basis. During the same period last year, the business earned $1.18 EPS. View PerkinElmer's earnings history.

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Thursday, January 23rd. Stockholders of record on Friday, April 17th will be paid a dividend of $0.07 per share on Friday, May 8th. This represents a $0.28 annualized dividend and a yield of 0.37%. The ex-dividend date of this dividend is Thursday, April 16th. View PerkinElmer's dividend history.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its first quarter earnings guidance on Monday, March, 9th. The company provided earnings per share (EPS) guidance of below $0.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.70. The company issued revenue guidance of below $700 million, compared to the consensus revenue estimate of $699.61 million.

What price target have analysts set for PKI?

14 analysts have issued 1 year target prices for PerkinElmer's shares. Their forecasts range from $41.00 to $115.00. On average, they expect PerkinElmer's stock price to reach $83.57 in the next twelve months. This suggests a possible upside of 11.7% from the stock's current price. View analysts' price targets for PerkinElmer.

Has PerkinElmer been receiving favorable news coverage?

Media stories about PKI stock have been trending very negative recently, InfoTrie reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PerkinElmer earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutPerkinElmer.

Are investors shorting PerkinElmer?

PerkinElmer saw a decline in short interest in February. As of February 14th, there was short interest totaling 4,950,000 shares, a decline of 13.3% from the January 30th total of 5,710,000 shares. Based on an average trading volume of 567,600 shares, the days-to-cover ratio is presently 8.7 days. Approximately 4.5% of the company's shares are short sold. View PerkinElmer's Current Options Chain.

Who are some of PerkinElmer's key competitors?

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), IBM (IBM), Home Depot (HD), Visa (V), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Thermo Fisher Scientific (TMO) and Adobe (ADBE).

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the following people:
  • Mr. Robert F. Friel, Chairman & CEO (Age 63)
  • Dr. Prahlad R. Singh, Pres & COO (Age 54)
  • Mr. James M. Mock, Sr. VP & CFO (Age 42)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 50)
  • Mr. James Corbett, Exec. VP and Pres of Discovery & Analytical Solutions (Age 56)

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital Research Global Investors (10.67%), Janus Henderson Group PLC (5.88%), Massachusetts Financial Services Co. MA (4.46%), State Street Corp (3.99%), King Luther Capital Management Corp (2.27%) and Pictet Asset Management Ltd. (2.27%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Pascale Witz, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View institutional ownership trends for PerkinElmer.

Which institutional investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Echo Street Capital Management LLC, First Trust Advisors LP, Williams Jones Wealth Management LLC., FMR LLC, Lord Abbett & CO. LLC, Nikko Asset Management Americas Inc., Artemis Investment Management LLP, and Bank of America Corp DE. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Deborah A Butters, Pascale Witz, and Prahlad R Singh. View insider buying and selling activity for PerkinElmer.

Which institutional investors are buying PerkinElmer stock?

PKI stock was bought by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Norges Bank, Massachusetts Financial Services Co. MA, KBC Group NV, Janus Henderson Group PLC, Pictet Asset Management Ltd., Alta Capital Management LLC, and Cannell Peter B & Co. Inc.. View insider buying and selling activity for PerkinElmer.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $74.80.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $8.33 billion and generates $2.88 billion in revenue each year. The medical research company earns $227.56 million in net income (profit) each year or $4.10 on an earnings per share basis. PerkinElmer employs 13,000 workers across the globe. View additional information about PerkinElmer.

What is PerkinElmer's official website?

The official website for PerkinElmer is http://www.perkinelmer.com/.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]


MarketBeat Community Rating for PerkinElmer (NYSE PKI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  467 (Vote Outperform)
Underperform Votes:  483 (Vote Underperform)
Total Votes:  950
MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe PKI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: CD Ladder

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel